
    
      This phase 3 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
      receptor tyrosine kinases, is to assess efficacy and safety in patients wiht advanced
      hepatocellular carcinoma (HCC).The study is a randomised,controlled,multicentre study.The
      controlled drug is sorafenib(Nexavar).The primary endpoint is overall survival.
    
  